User login
Patients with hepatitis C virus (HCV) infections may have the best long-term outcomes if they achieve sustained viral response (SVR) before they develop clinically significant portal hypertension, according to a study reported on in the July issue of Gastroenterology. On the other hand, patients in stage 2 cirrhosis were more likely than stage 1 patients to develop liver decompensation and to die of hepatocellular carcinoma, regardless of SVR. “The available evidence, including our own, suggests that it is opportune to treat HCV as early as possible, in order to reduce progression to stages of cirrhosis in which a viral cure may be less likely lead to ultimate achievement of a major benefit,” said Dr. Vito Di Marco and his associates from the University of Palermo, Italy. More on the study, and its limitations, is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/infectious-diseases/single-article-page/early-sustained-viral-response-linked-to-better-outcomes-among-hcv-patients/5089546903e73ad3c6947ff3bd3f8dbc.html.
Patients with hepatitis C virus (HCV) infections may have the best long-term outcomes if they achieve sustained viral response (SVR) before they develop clinically significant portal hypertension, according to a study reported on in the July issue of Gastroenterology. On the other hand, patients in stage 2 cirrhosis were more likely than stage 1 patients to develop liver decompensation and to die of hepatocellular carcinoma, regardless of SVR. “The available evidence, including our own, suggests that it is opportune to treat HCV as early as possible, in order to reduce progression to stages of cirrhosis in which a viral cure may be less likely lead to ultimate achievement of a major benefit,” said Dr. Vito Di Marco and his associates from the University of Palermo, Italy. More on the study, and its limitations, is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/infectious-diseases/single-article-page/early-sustained-viral-response-linked-to-better-outcomes-among-hcv-patients/5089546903e73ad3c6947ff3bd3f8dbc.html.
Patients with hepatitis C virus (HCV) infections may have the best long-term outcomes if they achieve sustained viral response (SVR) before they develop clinically significant portal hypertension, according to a study reported on in the July issue of Gastroenterology. On the other hand, patients in stage 2 cirrhosis were more likely than stage 1 patients to develop liver decompensation and to die of hepatocellular carcinoma, regardless of SVR. “The available evidence, including our own, suggests that it is opportune to treat HCV as early as possible, in order to reduce progression to stages of cirrhosis in which a viral cure may be less likely lead to ultimate achievement of a major benefit,” said Dr. Vito Di Marco and his associates from the University of Palermo, Italy. More on the study, and its limitations, is available at Family Practice News: http://www.familypracticenews.com/specialty-focus/infectious-diseases/single-article-page/early-sustained-viral-response-linked-to-better-outcomes-among-hcv-patients/5089546903e73ad3c6947ff3bd3f8dbc.html.